- Home
- AGMH vs BCAB Comparison
AGMH vs BCAB Comparison
Compare AGMH & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMH | BCAB |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.9M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AGMH | BCAB |
|---|---|---|
| Price | $0.99 | $3.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.2K | ★ 67.8K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.12 |
| 52 Week High | $18.10 | $6.52 |
Technical Indicators
Market Signals| Indicator | AGMH | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 42.50 |
| Support Level | $0.98 | $3.15 |
| Resistance Level | $1.15 | $4.24 |
| Average True Range (ATR) | 0.09 | 0.34 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 33.75 | 28.57 |
Price Performance
Historical ComparisonAbout AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is a technology company engaged in technology hardware research and development, manufacturing, assembly, and sales. Its core business segments include research and development of blockchain-oriented ASIC chips, production of high-end crypto miners for Bitcoin and other cryptocurrencies, and Fintech software services. The Company mainly derives revenue from the sales of cryptocurrency mining machines and standardized computing equipment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.